{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:17:36Z","timestamp":1791465456863,"version":"4.3.4"},"reference-count":144,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Spondyloarthritis (SpA) is a subset of seronegative rheumatic-related autoimmune diseases that consist of ankylosing spondylitis (AS), psoriatic spondylitis (PsA), reactive spondylitis (re-SpA), inflammatory bowel disease (IBD)-associated spondylitis, and unclassifiable spondylitis. These subsets share clinical phenotypes such as joint inflammation and extra-articular manifestations (uveitis, IBD, and psoriasis [Ps]). Inflammation at the enthesis, where ligaments and tendons attach to bones, characterizes and distinguishes SpA from other types of arthritis. Over the past several years, genetic, experimental, and clinical studies have accumulated evidence showing that the IL-23\/IL-17 axis plays a critical role in the pathogenesis of SpA. These discoveries include genetic association and the identification of IL-23- and IL-17-producing cells in the tissue of mouse models and human patients. In this review, we summarize the current knowledge of the pathomechanism by focusing on the IL-23\/IL-17 pathway and examine the recent clinical studies of biological agents targeting IL-23 and IL-17 in the treatment of SpA.<\/jats:p>","DOI":"10.3390\/ijms21176401","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T08:40:26Z","timestamp":1599122426000},"page":"6401","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["The Role of the IL-23\/IL-17 Pathway in the Pathogenesis of Spondyloarthritis"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-1210","authenticated-orcid":false,"given":"Hiroyuki","family":"Tsukazaki","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-2997","authenticated-orcid":false,"given":"Takashi","family":"Kaito","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00005792-197409000-00002","article-title":"Associations between ankylosing spondylitis, psoriatic arthritis, Reiter\u2019s disease, the intestinal arthropathies, and Behcet\u2019s syndrome","volume":"53","author":"Moll","year":"1974","journal-title":"Medicine"},{"key":"ref_2","unstructured":"Kellgren, J.H. (1963). Epidemiology of Chronic Rheumatism. Atlas of Standard Radiographs of Arthritis, Blackwell Science Ltd."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of Diagnostic Criteria for Ankylosing Spondylitis","volume":"27","author":"Valkenburg","year":"1984","journal-title":"Arthritis Rheum."},{"key":"ref_4","first-page":"85","article-title":"Criteria of the classification of spondylarthropathies","volume":"57","author":"Amor","year":"1990","journal-title":"Rev. Rhum. Mal. Osteoartic."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group Preliminary Criteria for the Classification of Spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/336079a0","article-title":"Cell-cell adhesion mediated by CD8 and MHC class I molecules","volume":"336","author":"Norment","year":"1988","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJM197304052881403","article-title":"High Association of an HL-A Antigen, W27, with Ankylosing Spondylitis","volume":"288","author":"Schlosstein","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: Etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing Spondylitis and Axial Spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1590\/S0365-05962012000600004","article-title":"HLA-B27 frequency in a group of patients with psoriatic arthritis","volume":"87","author":"Ruiz","year":"2012","journal-title":"An. Bras. Dermatol."},{"key":"ref_13","first-page":"S31","article-title":"The involvement of the spine in psoriatic arthritis","volume":"33","author":"Baraliakos","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ng.694","article-title":"A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1","volume":"42","author":"Strange","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/ni860","article-title":"The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8\u20139 residues","volume":"3","author":"York","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/art.24763","article-title":"HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats","volume":"60","author":"DeLay","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.humimm.2012.10.019","article-title":"Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet\u2019s disease","volume":"74","author":"Cenit","year":"2013","journal-title":"Hum. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.berh.2014.10.009","article-title":"The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it","volume":"28","author":"Jacques","year":"2014","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: From pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_23","first-page":"202","article-title":"Mechanical determinants of bone form: Insights from skeletal remains","volume":"5","author":"Ruff","year":"2005","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: Enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nri.2017.7","article-title":"Dysbiosis and the immune system","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrgastro.2012.152","article-title":"The gut microbiota in IBD","volume":"9","author":"Manichanh","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39259","article-title":"Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases","volume":"68","author":"Scher","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","article-title":"The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats","volume":"180","author":"Taurog","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm0911-1055","article-title":"Autoimmunity\u2019s collateral damage: Gut microbiota strikes \u201cback\u201d","volume":"17","author":"Cua","year":"2011","journal-title":"Nat. Med."},{"key":"ref_30","first-page":"414","article-title":"Microscopic gut inflammation in axial spondyloarthritis: A multiparametric predictive model","volume":"72","author":"Bosch","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","first-page":"1186","article-title":"Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: Results from the GIANT cohort","volume":"73","author":"Jans","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.38967","article-title":"Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis","volume":"67","author":"Costello","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_34","first-page":"715","article-title":"Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17","volume":"278","author":"Aggarwal","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23\u2013IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/07853890.2011.577093","article-title":"Interleukin-23: A key cytokine in inflammatory diseases","volume":"43","author":"Duvallet","year":"2011","journal-title":"Ann. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: As a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ibd.20894","article-title":"Interleukin-23\/Th17 pathways and inflammatory bowel disease","volume":"15","author":"Abraham","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00296-009-0883-x","article-title":"Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis","volume":"29","author":"Wang","year":"2009","journal-title":"Rheumatol. Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis","volume":"30","author":"Mei","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/ar3817","article-title":"Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features","volume":"14","author":"Celis","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/ard.2009.107649","article-title":"Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis","volume":"69","author":"Melis","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","article-title":"Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis","volume":"74","author":"Ciccia","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","article-title":"Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense","volume":"194","author":"Ye","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1086\/422329","article-title":"Requirement of Interleukin-17A for Systemic Anti\u2013Candida albicans Host Defense in Mice","volume":"190","author":"Huang","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","article-title":"IL-17 in the immunopathogenesis of spondyloarthritis","volume":"14","author":"Taams","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23\u2013IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11926-009-0052-y","article-title":"The role of interleukin-17 in the pathogenesis of rheumatoid arthritis","volume":"11","author":"Gaffen","year":"2009","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_58","first-page":"828","article-title":"Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis","volume":"29","author":"Jaimes","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","article-title":"Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis","volume":"74","author":"Wendling","year":"2007","journal-title":"Jt. Bone Spine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcma.2012.05.006","article-title":"Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis","volume":"75","author":"Chen","year":"2012","journal-title":"J. Chin. Med Assoc."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","article-title":"Levels of Circulating Th17 Cells and Regulatory T Cells in Ankylosing Spondylitis Patients with an Inadequate Response to Anti\u2212TNF-\u03b1 Therapy","volume":"33","author":"Xueyi","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"ref_62","first-page":"2285","article-title":"Th1\/Th17 cytokine profiles in patients with reactive arthritis\/undifferentiated spondyloarthropathy","volume":"34","author":"Singh","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/art.27622","article-title":"Role of Th17 cells in human autoimmune arthritis","volume":"62","author":"Leipe","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2011","journal-title":"Mol. Cell. Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17\u2013producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-\u03b2 induces development of the TH17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3899\/jrheum.100146","article-title":"Frequency and Phenotype of T Helper 17 Cells in Peripheral Blood and Synovial Fluid of Patients with Reactive Arthritis","volume":"37","author":"Shen","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/eji.201242569","article-title":"IL-17-producing \u03b3\u03b4 T cells and innate lymphoid cells","volume":"42","author":"Sutton","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.4049\/jimmunol.181.5.3456","article-title":"IL-17A Produced by \u03b3\u03b4 T Cells Plays a Critical Role in Innate Immunity against Listeria monocytogenes Infection in the Liver","volume":"181","author":"Hamada","year":"2008","journal-title":"J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nri.2017.101","article-title":"\u03b3\u03b4 T cells in homeostasis and host defence of epithelial barrier tissues","volume":"17","author":"Nielsen","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.coi.2008.03.006","article-title":"\u03b3\u03b4 T cells: An important source of IL-17","volume":"20","author":"Roark","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 Induce Innate IL-17 Production from \u03b3\u03b4 T Cells, Amplifying Th17 Responses and Autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma\/delta T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cei.12853","article-title":"Interleukin (IL)-9\/IL-9R axis drives \u03b3\u03b4 T cells activation in psoriatic arthritis patients","volume":"186","author":"Guggino","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Martin, E., Treiner, E., Duban, L., Guerri, L., Laude, H., Toly, C., Pr\u00e9mel, V., Devys, A., Moura, I.C., and Tilloy, F. (2009). Stepwise development of MAIT cells in mouse and human. PLoS Biol., 7.","DOI":"10.1371\/journal.pbio.1000054"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/jid.2014.261","article-title":"The IL-17A-Producing CD8 + T-Cell Population in Psoriatic Lesional Skin Comprises Mucosa-Associated Invariant T Cells and Conventional T Cells","volume":"134","author":"Teunissen","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3899\/jrheum.151133","article-title":"Involvement of Mucosal-associated Invariant T cells in Ankylosing Spondylitis","volume":"43","author":"Hayashi","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Toussirot, \u00c9., Laheurte, C., Gaugler, B., Gabriel, D., and Saas, P. (2018). Increased IL-22- and IL-17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients With Ankylosing Spondylitis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01610"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells\u2014A proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nri3855","article-title":"Transcriptional regulation of innate lymphoid cell fate","volume":"15","author":"Serafini","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","article-title":"Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis","volume":"200","author":"Soare","year":"2018","journal-title":"J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/art.40150","article-title":"Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis","volume":"69","author":"Cuthbert","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3892\/etm.2014.2046","article-title":"T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis","volume":"9","author":"Wang","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/s41467-017-01771-2","article-title":"Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis","volume":"8","author":"Chen","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2017.03.016","article-title":"IL-17 and IFN-\u03b3 producing NK and \u03b3\u03b4-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis","volume":"183","author":"Chowdhury","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_98","first-page":"A8","article-title":"O016 Synovial IL-17+ CD8+ T cells are a pro-inflammatory tissue resident population enriched in spondyloarthritis","volume":"77","author":"Steel","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e001149","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in TNFi-na\u00efve active psoriatic arthritis patients with physician-reported spondylitis: Pooled results from two phase 3, randomised, controlled trials","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD Open"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23\u2013IL-17 immune axis: From mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41584-020-0420-6","article-title":"IL-23 inhibitor guselkumab shows promise for PsA","volume":"16","author":"McHugh","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5114\/reum.2019.87620","article-title":"Tildrakizumab in the treatment of psoriasis\u2014literature review","volume":"57","author":"Banaszczyk","year":"2019","journal-title":"Reumatologia"},{"key":"ref_108","first-page":"78","article-title":"Lb0002 Randomised, Double-blind, Placebo-controlled, Multiple-dose, Phase 2b Study to Demonstrate the Safety and Efficacy Of Tildrakizumab, a High-affinity Anti-interleukin-23p19 Monoclonal Antibody, un Patients with Active Psoriatic Arthritis","volume":"78","author":"Mease","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti\u2013IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_111","first-page":"200","article-title":"OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: Results from a phase 2 trial","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: A randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_117","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","article-title":"Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study","volume":"20","author":"Coates","year":"2018","journal-title":"Arthritis Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","article-title":"Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study","volume":"2","author":"McInnes","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): A double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J. Inflamm. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/bjd.16497","article-title":"Ixekizumab or secukinumab in psoriasis: What difference does it make?","volume":"178","author":"Paul","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bjd.16140","article-title":"Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs","volume":"178","author":"Warren","year":"2018","journal-title":"secukinumab. Br. J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Chandran, V., Van Der Heijde, D., Fleischmann, R.M., Lespessailles, E., Helliwell, P.S., Kameda, H., Burgos-Vargas, R., Erickson, J.S., Rathmann, S.S., and Sprabery, A.T. (2020). Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology.","DOI":"10.1093\/rheumatology\/kez684"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"Wei","year":"2018","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Kostareva, O.S., Kolyadenko, I., Ulitin, A., Ekimova, V., Evdokimov, S., Garber, M., Tishchenko, S.V., and Gabdoulkhakov, A. (2019). Fab Fragment of VHH-Based Antibody Netakimab: Crystal Structure and Modeling Interaction with Cytokine IL-17A. Crystals, 9.","DOI":"10.3390\/cryst9030177"},{"key":"ref_129","first-page":"27","article-title":"Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults","volume":"38","author":"Erdes","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_130","first-page":"1690","article-title":"AB0791 Netakimab Reduces Skin Manifestations of Psoriatic Arthritis: Results of Subanalysis From a Double-blind Randomized Phase 3 Study (Patera)","volume":"79","author":"Korotaeva","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_131","first-page":"193","article-title":"OP0232 Netakimab Reduces the Disease Activity of Radiographic Axial Spondyloarthritis","volume":"78","author":"Gaydukova","year":"2019","journal-title":"Results of Astera Study. Ann. Rheum. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/jid.2012.163","article-title":"Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial","volume":"132","author":"Papp","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14712598.2019.1554053","article-title":"Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis","volume":"19","author":"Wendling","year":"2018","journal-title":"Expert Opin. Boil. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(20)30220-8","article-title":"Inhibition of interleukins 17A and 17F in psoriatic arthritis","volume":"395","author":"Nash","year":"2020","journal-title":"Lancet"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: Results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"Gensler","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/annrheumdis-2014-eular.4676","article-title":"FRI0303 Discovery and Characterization of Abt-122, an Anti-TNF\/IL-17 Dvd-Ig\u2122 Molecule as A Potential Therapeutic Candidate for Rheumatoid Arthritis","volume":"73","author":"Hsieh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","article-title":"Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: Open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/key312","article-title":"Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis","volume":"58","author":"Khatri","year":"2019","journal-title":"Rheumatology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab Induction and Maintenance Therapy in Refractory Crohn\u2019s Disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6401\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:06:09Z","timestamp":1760177169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":144,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ijms21176401"],"URL":"https:\/\/doi.org\/10.3390\/ijms21176401","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]}}}